Tamada, Satoshi
Osaka City University Hospital
2 papers on CoChatORCID 0000-0002-7102-3408
Most cited papers
- Verified
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 3,403
- Verified
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 751
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free